636 results on '"Fournier,Keith"'
Search Results
52. Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases
53. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma
54. Risk of relapse after surgical resection of localized appendiceal adenocarcinoma.
55. Utility of gene expression–based cancer classification in diagnosis of malignant peritoneal mesothelioma (MPeM): Filling in the gaps in standard pathologic work-up for a rare cancer.
56. Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts
57. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique
58. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy
59. Patient Selection for Cytoreductive Surgery
60. ASO Visual Abstract: What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?
61. Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative
62. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative
63. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study
64. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit
65. Data from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
66. Supplementary Figures from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
67. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma
68. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer
69. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases
70. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy
71. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved
72. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial
73. Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
74. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma
75. Defining the Impact of Surgical Approach on Perioperative Outcomes for Patients with Gastric Cardia Malignancy
76. Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates
77. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer
78. Abstract 6546: Peritoneal microenvironment promotes appendiceal adenocarcinoma tumor formation in PDX models
79. Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
80. Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
81. Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
82. Supplementary Data from Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers
83. Data from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
84. Supplementary Figure 1 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
85. Supplementary Figure 3 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
86. Supplementary Figure 2 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
87. Supplementary Figure Legends 1-6, Tables 1-2 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
88. Supplementary Figure 5 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
89. Supplementary Table 3 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
90. Supplementary Figure 4 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
91. Supplementary Figure 6 from Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
92. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy
93. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy
94. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma
95. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy
96. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm
97. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer
98. Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
99. A prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma.
100. Utility of tumor marker levels in predicting survival of patients with appendiceal adenocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.